Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

• Main Authors: Nickles, Emily, Dharmadhikari, Bhushan, Li, Yating, Walsh, Robert J, Koh, Liang Piu, Poon, Michelle, Tan, Lip Kun, Wang, Ling-Zhi, Ang, Yvonne, Asokumaran, Yugarajah, Chong, Wan Qin, Huang, Yiqing, Loh, Kwok Seng, Tay, Joshua, Soo, Ross, Koh, Mickey, Ho, Liam Pock, Chan, Marieta, Niam, Madelaine, Soh, Melissa, Luah, Yen Hoon, Lim, Chwee Ming, Kaliaperumal, Nivashini, Au, Veonice B, Talib, Najwa Binte Said Nasir, Sng, Reina, Connolly, John E, Goh, Boon Cher, Schwarz, Herbert
• Other Authors: BIOMED INST FOR GLOBAL HEALTH RES & TECH
• Format: Article
• Language: English
• Published: SPRINGER 2023
• Subjects: Science & Technology; Life Sciences & Biomedicine; Oncology; Immunology; Nasopharyngeal carcinoma; CD137L-DC; Dendritic cell immunotherapy; EBV; Phase 1 clinical trial; CD137 LIGAND; T-CELLS; LYMPHOCYTE-ACTIVATION; PHASE-II; MONOCYTE; IMMUNOTHERAPY; RECEPTOR; MEMBER; DIFFERENTIATION; PROLIFERATION
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/239112
• Institution: National University of Singapore

10.1007/s00262-021-03075-3